BridgeMD
Prevention study for Postpartum Hemorrhage
Official title Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage
ClinicalTrials.gov ID: NCT07401524
What this study is testing
What is Carbetocin?
Carbetocin is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for postpartum hemorrhage.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this clinical trial is to learn if the drug carbetocin works better than standard care to prevent heavy bleeding after childbirth in people carrying twin pregnancies. Heavy bleeding after delivery, also called postpartum hemorrhage, is more common after twin births and can lead to anemia, blood transfusions, and other serious health problems.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, women only
You may be able to join if
- Pregnant individuals aged ≥18 years
- Twin pregnancies
- Gestational age ≥23 weeks
You likely can't join if
- Known hypersensitivity or contraindication to carbetocin
- Higher-order multiple gestation (triplets or more)
- Maternal age \<18 years
- Known placenta accreta spectrum
- Known bleeding disorder
- Intrauterine fetal death of one or more fetuses
See the full eligibility criteria
- Pregnant individuals aged ≥18 years
- Twin pregnancies
- Gestational age ≥23 weeks
- Known hypersensitivity or contraindication to carbetocin
- Higher-order multiple gestation (triplets or more)
- Maternal age \<18 years
- Known placenta accreta spectrum
- Known bleeding disorder
- Intrauterine fetal death of one or more fetuses
- Hyponatremia precluding oxytocin use
- Planned delivery at a non-participating hospital
The study team makes the final eligibility decision.
Where it's taking place
- Ramat Gan, Israel
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Ramat Gan, Israel. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.